Update shared on 14 Oct 2025
Fair value Decreased 5.31%Analysts have lowered their price target for Vitrolife from SEK 202.50 to SEK 191.75. This reflects updated expectations for slower revenue growth and profit margins, as well as a slightly higher discount rate.
Valuation Changes
- Fair Value Estimate: Decreased from SEK 202.50 to SEK 191.75, reflecting a lower valuation outlook.
- Discount Rate: Increased slightly from 4.95% to 5.10%, indicating a marginally higher required rate of return.
- Revenue Growth: Lowered from 6.37% to 5.83%, signaling more cautious growth expectations.
- Net Profit Margin: Decreased from 20.30% to 18.62%, pointing to anticipated pressure on profitability.
- Future P/E: Increased from 36.52x to 38.45x, suggesting relatively higher valuation multiples despite the revised outlook.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.